Specifically, higher rates of NASH, as well as hepatic steatosis, inflammation, and fibrosis were observed in Hp(+) than Hp(−) patients, findings warranting further investigation. This evidence concerns the gene HP and metabolic dysfunction-associated steatohepatitis.